Evidence map›Paper›PMID 39367565›Full record

ArticleFEBS open bio2024

PRMT1-mediated arginine methylation promotes YAP activation and hepatocellular carcinoma proliferation.

Jian Yu, Beibei Yu, Zushun Peng, Jianfeng Zhang, Juhui Sun, Bo Yang, Liushiyang Xu, De Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jian YuXiangshan First People's Hospital Medical and Health Group, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Luzhou, China.
Beibei YuXiangshan First People's Hospital Medical and Health Group, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Luzhou, China.
Zushun PengXiangshan First People's Hospital Medical and Health Group, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Luzhou, China.
Jianfeng ZhangXiangshan First People's Hospital Medical and Health Group, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Luzhou, China.
Juhui SunXiangshan First People's Hospital Medical and Health Group, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Luzhou, China.
Bo YangXiangshan First People's Hospital Medical and Health Group, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Luzhou, China.
Liushiyang XuXiangshan First People's Hospital Medical and Health Group, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Luzhou, China.
De LuoDepartment of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.ORCID https://orcid.org/0009-0008-4317-2183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The activity of Hippo signaling is commonly dysregulated in various human malignancies, including hepatocellular carcinoma (HCC). YAP, the key effector of Hippo pathway, is regulated through several posttranslational modifications. However, the mechanism by which YAP is regulated by arginine methylation remains unknown. In this study, immunoprecipitation and mass spectrometry were used to identify the arginine methylation site of YAP in HCC cells. The transcriptional activity of YAP and TEAD were further characterized by real-time qPCR and immunofluorescence assay, and a subcutaneous and orthotopic tumor mouse model was used to assess the effect of PRMT1-knockdown on HCC tumor growth. The result of mass spectrometry analysis identified that YAP was methylated at arginine 124. Moreover, we found that arginine methyltransferase PRMT1 interacted with YAP to mediate its arginine methylation, thus inhibited YAP phosphorylation and promoted YAP activity in the nucleus. PRMT1 was up-regulated in HCC tissues and positively associated with the expressions of YAP target genes. Silencing PRMT1 in HCC cells inhibited cell proliferation and tumor growth, while PRMT1-overexpression promoted HCC growth through YAP methylation. Our study reveals that PRMT1-mediated arginine methylation at R124 is mutually exclusive with YAP S127 phosphorylation, thereby facilitating YAP activity in the nucleus and promoting tumorigenesis in HCC.

Indexed as

ArginineCarcinoma, HepatocellularCell ProliferationLiver NeoplasmsProtein-Arginine N-MethyltransferasesTranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMethylationMiceMice, Inbred BALB CAdaptor Proteins, Signal TransducingArgininePRMT1 protein, humanProtein-Arginine N-MethyltransferasesRepressor ProteinsTranscription FactorsYAP1 protein, humanYAP-Signaling Proteinshepatocellular carcinomaHippoPRMT1YAP

Identifiers

PMID39367565
PMCPMC11609590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.